BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD.
暂无分享,去创建一个
E. Jabbour | F. Turturro | U. Popat | Wei Wei | A. Alousi | R. Bassett | P. Anderlini | G. Rondón | I. Khouri | B. Oran | S. Ciurea | M. Korbling | A. Gulbis | Saira S. Ahmed | G. Rondon
[1] H. Greinix,et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease , 2015 .
[2] E. Jabbour,et al. Bfr (bendamustine, fludarabine, rituximab) Vs. FCR Nonmyeloablative Allogeneic Conditioning In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Outcome Results Including Minimal Residual Disease Analysis , 2013 .
[3] E. Jabbour,et al. Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning: A Novel Regimen Inducing Immunosuppression Without Myelosuppression , 2013 .
[4] M. Tatsumi,et al. Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] H. Deeg,et al. Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] M. Stauch,et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial , 2013, The Lancet.
[7] R. Champlin,et al. Nonmyeloablative Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma , 2012, Cancer journal.
[8] H. Döhner,et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] W. Erwin,et al. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. , 2012, Blood.
[10] C. Bueso-Ramos,et al. Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia , 2011, Cancer.
[11] M. Gobbi,et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. , 2011, Blood.
[12] Michael Boeckh,et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. , 2010, The New England journal of medicine.
[13] E. Kimby,et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] L. Medeiros,et al. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. , 2009, Blood.
[15] Bruce D Cheson,et al. Bendamustine: rebirth of an old drug. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] J. Radich,et al. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Michael Hallek,et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. , 2008, Blood.
[18] M. Sorror,et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Jacques Corbeil,et al. Bendamustine (Treanda) Displays a Distinct Pattern of Cytotoxicity and Unique Mechanistic Features Compared with Other Alkylating Agents , 2008, Clinical Cancer Research.
[20] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Daniel Wolff,et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[22] M. Hansmann,et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] N. Schmitz,et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation , 2003, Bone Marrow Transplantation.
[24] B. E. C. Oiffier,et al. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .
[25] E D Thomas,et al. 1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.
[26] J O'Quigley,et al. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. , 1990, Biometrics.
[27] E. Holler,et al. Graft-versus-host disease , 2009, The Lancet.
[28] R. Advani,et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] H. Signorelli. Blockade of Lymphocyte Chemotaxis in Visceral Graft-Versus-Host Disease , 2013 .
[30] R. Houot,et al. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] M. Turner,et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[32] R. Gray. A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .